Information  X 
Enter a valid email address

K.S. Biomedix Hldgs (FOGC)


Monday 28 October, 2002

K.S. Biomedix Hldgs

Product Agreement

K.S. Biomedix Holdings PLC
28 October 2002

Embargoed until 0700                        28 October 2002

KS Biomedix Holdings plc                                Tel: +44 (0) 1483 307500
Steven Powell, Chief Executive Officer

Weber Shandwick Square Mile                           Tel:  +44 (0) 20 7950 2800
Kevin Smith
Graham Herring

  KS Biomedix signs Agreement with Ranbaxy for TransMIDTM Brain Cancer Product

Guildford, UK, ... KS Biomedix Holdings plc ('KSB') (LSE: KSB) announces that it
has entered into an exclusive Agreement with Ranbaxy Laboratories Limited 
('Ranbaxy') for marketing TransMIDTM a novel biopharmaceutical product for
treatment of brain cancer, in India.  KSB and Ranbaxy have an option to extend
the coverage of this agreement to other South East Asian markets.

This latest agreement is the fourth territory licensed for TransMIDTM by KSB
since it acquired the technology in July 2001.  Nycomed was appointed as the
European licensee in a $60 million deal last month, Sosei as the Japanese
licensee in a $25 million deal in May 2002 and an agreement with Medison Pharma
for distribution of TransMIDTM in Israel was announced earlier this month.

TransMIDTM is a novel biopharmaceutical product in development for the
treatment of high grade glioma, a terminal brain cancer for which there is no
known cure.  A completed Phase II study conducted in leading neuro-oncology
centres in the USA showed highly promising clinical response rates and an
improvement in survival times in patients with recurrent brain cancer.  The FDA
has granted TransMIDTM Fast Track status and Orphan Drug Status for the
treatment of malignant tumours of the central nervous system and the EMEA
granted Orphan designation for the treatment of glioma in March 2002.

Under the terms of the agreement, Ranbaxy will have exclusive marketing and
distribution rights for TransMIDTM  product for brain cancer indications within
India in return for milestones commensurate with the size of the market
opportunity and a substantial distribution margin.

Steven Powell, KSB Chief Executive Officer, commented: 'This latest agreement is
the fourth territory licensed for TransMID this year, extending the commercial
coverage for the product significantly.  Ranbaxy is an excellent partner and
will support TransMID strongly in the region.'

Dr. Brian Tempest, Ranbaxy President-Pharmaceuticals, said, 'Ranbaxy is
committed to building relationships at a global level to bring cutting edge
technologies and products to India. The emerging IPR scenario will demand
extensive networking amongst pharmaceutical companies and Ranbaxy is well
positioned to lead this trend. We will continue to provide novel products for
Indian customers and are very excited to add TransMIDTM to our portfolio and
believe that this product will help us strengthen our position in the high value
Oncology Segment'.

                                    - Ends -

Notes to Editors

KS Biomedix Holdings Plc (Guildford, UK) is a biopharmaceutical company
headquartered in the UK that is developing a pipeline of drugs for a range of
cancer indications.  In addition, it has a number of technology platforms based
on its range of receptor-based targeting technologies. The Company has six
active clinical programmes, including TransMID-107RTM for the treatment of
adult, recurrent, inoperable high-grade gliomas (brain tumours) and KSB303, an
anti-CEA antibody for the diagnosis and treatment of cancer.

KS Biomedix was founded in 1993 and floated on the Alternative Investment Market
of the London Stock Exchange in 1995.  The Company joined the Official List of
the London Stock Exchange in 1998.

For more information please see

Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company,
manufactures and markets branded generic pharmaceuticals and Active
Pharmaceutical Ingredients (APIs).  Ranbaxy's continued focus on R&D has
resulted in several approvals in developed markets and significant progress in
New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems
(NDDS) has led to several proprietary know-how 'platform technologies' resulting
in many products under developmental/commercial stages.  The company is selling
its products in over 100 countries and has an expanding international portfolio
of affiliates, joint ventures and alliances, ground operations in 25 countries
and manufacturing operations in 7 countries.

For more information please visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                                                                    

a d v e r t i s e m e n t